Immunotherapy has emerged as a crucial treatment for NSCLC by stimulating the patient’s immune system to identify and eliminate tumor cells, with ICIs such as PD-1/PD-L1 and CTLA-4 inhibitors being integral to this mechanism (159). This evidence concerns the gene CD274 and non-small cell lung carcinoma.